Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.6K citations · Full text

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Keith T. Flaherty, Igor Puzanov, Kevin B. Kim et al. · New England Journal of Medicine · 2010 · 3.5K citations · Full text

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

Christine H. Chung, Beloo Mirakhur, Emily Chan et al. · New England Journal of Medicine · 2008 · 1.5K citations · Full text

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro et al. · New England Journal of Medicine · 2012 · 1.4K citations · Full text

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki et al. · The Lancet Oncology · 2011 · 910 citations

Hematological Malignancy, Oncology, Relapsed Multiple Myeloma +7